Imaging Diagnostic Systems (fka IMDS)

[ProfitScout]

European Institute of Oncology Receives CT Laser Breast Imaging System

Sixth CT Laser Mammography System in Italy

FORT LAUDERDALE, Fla., Oct 24, 2005 /PRNewswire-FirstCall via COMTEX/ -- Imaging Diagnostic Systems, Inc., ( IMDS ) announced today that a CT Laser Mammography (CTLM(R)) system will be installed at the prestigious European Institute of Oncology (EIO) in Milan, Italy. Studies will be performed under the auspices of Professor Umberto Veronesi, Scientific Director.

Professor Veronesi is the Chairman of the Institute's Scientific Committee, a group that suggests new areas of research for the Institute and monitors the research that is underway. Veronesi is also a member of the Institute's Research Committee, which decides the Institute's research strategy and approves research plans.

"We are extremely pleased that Professor Veronesi and his team will be using CTLM. His group has led many important studies; it is fitting that our revolutionary technology to improve the accuracy of breast cancer detection techniques and to improve case management move forward under their capable direction. We especially thank our local distributor for making this arrangement possible," stated Tim Hansen, Chief Executive Officer, Imaging Diagnostic Systems, Inc. "This marks our fourth sale in Italy and our sixth installation in the country -- a tremendous start for our clinical and commercialization efforts."

Dr. Enrico Cassano, Director of Breast Imaging at the Institute, said, "We are pleased to have this opportunity to work with the CTLM laser breast scanner. It has been used in research and in a clinical capacity at other international sites; now, we will add our expertise to that of the facilities working with this emergent modality. We are confident that our results will confirm the capabilities of CTLM."

The European Institute of Oncology is a comprehensive cancer center, providing diagnostic services and treatment while conducting research and participating in clinical trials. It is one of 30 institutes in Italy declared a Research Institute of Public Interest by the Italian government, a designation which reflects the strong national and international significance of the institutes to which the title is bestowed.

The sale, arranged through an IDSI distributor, was recognized in the fiscal quarter ending September 30, 2005.

The CTLM(R) system is the first patented breast imaging system that utilizes state-of-the-art laser technology and patented algorithms to create 3-D cross-sectional images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000- 13488 certification and FDA export certification for its CT Laser Breast Imaging system. The Company is seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLM(R) system to be used as an adjunct to mammography.

Please visit Imaging Diagnostic Systems' website at: http://www.imds.com for additional information.

In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company's filing with the Securities Exchange Commission.

Investor Relations:
Rick Lutz
404-261-1196
[e-mail]


SOURCE Imaging Diagnostic Systems, Inc.

Rick Lutz for Imaging Diagnostic Systems, Inc., [phone],
[e-mail]

http://www.prnewswire.com


Copyright (C) 2005 PR Newswire. All rights reserved.